TR563

TR563 is a preclinical-stage small molecule bisphosphonate formulated as a topical gel for the treatment of osteoporosis. Developed by Tritech Biopharmaceuticals, a Taiwan-based biotech specializing in non-invasive drug delivery, the drug utilizes a proprietary high-throughput screening platform for transdermal enhancers to facilitate delivery through the skin. Its mechanism of action involves binding to bone mineral and inhibiting osteoclast-mediated bone resorption, which is the standard antiresorptive approach for the bisphosphonate class. By employing a topical (transdermal) route of administration, TR563 aims to offer a non-invasive alternative to oral or injectable bisphosphonates, potentially reducing gastrointestinal side effects and improving patient compliance and ease of use.